Statin Therapy Vs. Therapeutic Lifestyle Changes and Supplements
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Randomized trial in a primary prevention population
- all participants have high LDL cholesterol
Group one will take simvastatin 40 mg/day Group Two will make therapeutic lifestyle changes,and take supplements consisting of red yeast rice and fish oil
| Condition | Intervention |
|---|---|
|
Hyperlipidemia |
Drug: simvastatin Drug: red yeast rice Drug: pharmaceutical grade fish oil Behavioral: therapeutic lifestyle changes |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Simvastatin Vs Therapeutic Lifestyle Changes and Supplements: A Primary Prevention Randomized Trial |
- LDL-c cholesterol
- total cholesterol
- HDL
- Triglycerides
- cardiac CRP
| Estimated Enrollment: | 80 |
| Study Start Date: | April 2006 |
| Estimated Study Completion Date: | June 2006 |
This is a randomized primary prevention trial to compare the LDL lowering effects of an alternative regimen to statins(simvastatin) This alternative regimen is over the counter and available at health food stores. The alternative regimen consists of lifestyle changes including a Mediterranean Diet,exercise program, and stress reduction, with red yeast rice 1200 mg twice per day and fish oil 6 grams/day. The second group, run at the same time will take Zocor(simvastatin) 40 mg per day with standard counseling
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adults ages 18-75 yrs, who meet ATP III criteria to be treated for high cholesterol. All participants must be able to exercise and be willing to be randomized to either arm of the study
Exclusion Criteria:
- No history of bypass surgery, stents, or hx of myocardial infarction. Cannot have uncontrolled hypertension(SBP>190 or DBP>100), cannot have known intolerance to one of the study drug
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00365742 History of Changes |
| Other Study ID Numbers: | FWA00005390-Chestnut Hill Hosp |
| Study First Received: | August 16, 2006 |
| Last Updated: | August 16, 2006 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Chestnut Hill Health System:
|
red yeast rice pharmaceutical grade fish oil simvastatin primary prevention |
Additional relevant MeSH terms:
|
Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Simvastatin Red yeast rice Hypolipidemic Agents Antimetabolites |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Lipid Regulating Agents Therapeutic Uses Hydroxymethylglutaryl-CoA Reductase Inhibitors Anticholesteremic Agents Enzyme Inhibitors |
ClinicalTrials.gov processed this record on May 23, 2013